An Open-label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between SAM-531 and Gemfibrozil, a Cytochrome P-450 2C8 Inhibitor, When Coadministered Orally to Healthy Young Adult Subjects.

Trial Profile

An Open-label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between SAM-531 and Gemfibrozil, a Cytochrome P-450 2C8 Inhibitor, When Coadministered Orally to Healthy Young Adult Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Aug 2010

At a glance

  • Drugs Cerlapirdine; Gemfibrozil
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 02 Feb 2010 Actual patient number (17) added as reported by ClinicalTrials.gov.
    • 02 Feb 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 02 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top